Migraine and female hormones -what factors increase the risk of ischemic stroke?
(IHS), gives some of the more recent studies greater credibility. 13 Even then, few studies have used face-to-face questioning to elicit the diagnosis. 2, 3, 10 Assuming the risk is real, what mechanisms might account for increased ischemic stroke in healthy women with migraine using COCs? One possible mechanism that has not been fully explored is the effect of ethinylestradiol on platelets. Platelet hyperaggregation is associated with the use of COCs but the degree to which it occurs is extremely variable. This is due to the marked individual variation in plasma levels of ethinylestradiol in COC users. 14, 15 Although data are conflicting, there is evidence in favor of increased platelet hyperaggregability in migraine aura. In particular, Hanington et al showed that platelets from patients with migraine with aura showed increased aggregation to 5-hydroxytriptamine (5HT). 16 More importantly, women developed migraine after the onset of COC use in association with increased platelet aggregation to 5HT. Cessation of COCs led to a gradual reduction in the frequency of attacks that were associated with a significant reduction in the extent and rate of platelet aggregation in response to 5HT. Other researchers have reported similar findings. However, these studies are open to significant criticism and, although the arguments are persuasive to some, there is a paucity of research to support this or any other purported mechanism to date.
The effects of hormone replacement therapy (HRT) on migraine and ischemic stroke are not fully known. Postmenopausal hormone use is not generally considered to be associated with an increase or decrease in the risk of ischemic stroke. Contrary to this, some recent surveys comparing the relatively small group of current users to the large group of never and past users have found a significant increase in TIAs and ischemic strokes. 17, 18 It is recognized that use of HRT, usually associated with beneficial effects on blood clotting, can lead to a hypercoagulable state in some women. There are reports of women with a history of aura-free migraines developing aura after starting HRT, which were resolved following reduction in the dose, or withdrawal, of estrogens. 19, 20 However, in the absence of data to suggest that aura is associated with an increased risk of ischemic stroke in women using HRT, there is no contraindication to its use in these women, although the minimum necessary dose of estrogen is recommended.
Reducing the risk of ischemic stroke
Whatever the limitations of the studies that have identified an increased risk of ischemic stroke in young women with migraine and, whatever the mechanism, is any intervention justified? For the majority of women with migraine, probably not, given the low absolute risk of ischemic stroke. However, the apparent synergism between migraine and use of COCs does justify active detection and (if possible) correction of other risk factors. Blood pressure should be checked routinely, and all COC users should be advised to stop smoking. What about women with migraine with aura in whom use of COCs appears to be associated with a risk of ischemic stroke that is greater than the risk associated with the condition they are trying to prevent, i.e. pregnancy? Some authorities, such as the World Health Organisation and the Faculty of Family Planning of the Royal College of Obstetricians and Gynacecologists, consider that COCs should be contraindicated in these women. 21, 22 Others, including the IHS, are more permissive. 23 Fortunately, the percentage of women with migraine with aura in the age-group requiring contraception is small. Therefore the number of women affected by the recommendation not to use, or to discontinue use of, COCs is small. Of great concern is that these women should not be denied effective contraception. This is not an issue as there are several nonethinylestradiol methods, many of which are more effective contraceptives than COCs. These include injectable progestogens (depot medroxyprogesterone acetate and norethisterone enanthate), progestogen implants, levonorgestrel intrauterine devices, copper intrauterine devices, and male and female sterilization. The progestogen-only pill can also be considered but is less effective than COCs in young women. Women using progestogen-only methods can be reassured that there is no evidence that their use is associated with an increased risk of ischemic stroke. 24, 25 Until more definitive data are available, ideally from prospective studies, a difficult balance has to be struck between reducing the potential for ischemic stroke in a subgroup of migraineurs at greatest risk while avoiding the unnecessary exclusion of many women from a useful contraceptive. In deciding whether or not COCs should be contraindicated in any individual at risk of ischemic stroke, perhaps we should consider the words of Bickerstaff from his 1975 monograph: 'If one saves only one young woman from hemiplegia it is a justified precaution'. 26 
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